Pharmacoeconomic report: Apomorphine hydrochloride (Kynmobi) (Sunovion Pharmaceuticals Canada Inc.) indication: the acute, intermittent treatment of "OFF" episodes in patients with Parkinson disease

CADTH undertook reanalyses to address uncertainty regarding the clinical benefits of apomorphine hydrochloride sublingual (APO SL) film. Aligned with the CADTH Clinical Review, given no differences in clinical efficacy or harms could be concluded, CADTH assumed: equal efficacy with respect to reduct...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2021, April 2021
Edition:	Final (with redactions)
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK572562
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa